Related references
Note: Only part of the references are listed.Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma (vol 23, pg 3, 2009)
R. A. Kyle et al.
LEUKEMIA (2014)
Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen - A national multicenter study
Wojciech Jurczak et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy
Gaetano Corazzelli et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
M. S. Aapro et al.
EUROPEAN JOURNAL OF CANCER (2011)
Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma
Matteo Dell'olio et al.
LEUKEMIA & LYMPHOMA (2011)
Nonpegylated liposomal doxorubicin is highly active in patients with B and T/NK cell lymphomas with cardiac comorbidity or higher age
Daniel Heintel et al.
ANNALS OF HEMATOLOGY (2010)
Nonpegylated liposomal doxorubicin (Myocet™) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial
S. Luminari et al.
ANNALS OF ONCOLOGY (2010)
Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines
D. Bovelli et al.
ANNALS OF ONCOLOGY (2010)
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
Bertrand Coiffier et al.
BLOOD (2010)
Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials
Lesley A. Smith et al.
BMC CANCER (2010)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Michael Hallek et al.
BLOOD (2008)
Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma
Dawn L. Hershman et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Advantages of liposomal delivery systems for anthracyclines
TM Allen et al.
SEMINARS IN ONCOLOGY (2004)
Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma
S Limat et al.
ANNALS OF ONCOLOGY (2003)
Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients
T Nousiainen et al.
BRITISH JOURNAL OF CANCER (2002)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma
L Harris et al.
CANCER (2002)
Share Paper
